CHEK1 and neoplasm: As ecDNA+-oncogene-amplified tumour cells harbour elevated intrinsic RS and are sensitive to other CHK1 inhibitors (Fig. 3d), we hypothesized that they would also be hypersensitive to BBI-2279.